

Daniela Maria Cardinale

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4329482/daniela-maria-cardinale-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94
papers

8,368
citations

36
h-index

91
g-index

102
ext. papers

10,385
ext. citations

9.7
avg, IF

5.59
L-index

#	Paper	IF	Citations
94	Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. <i>Circulation</i> , 2015 , 131, 1981-8	16.7	776
93	Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 213-20	15.1	732
92	Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Journal of the American Society of Echocardiography</i> , 2014 , 27, 911-39	5.8	722
91	Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. <i>Circulation</i> , 2006 , 114, 2474-81	16.7	696
90	Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. <i>Circulation</i> , 2004 , 109, 2749-54	16.7	652
89	Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2014 , 15, 1063-93	4.1	526
88	Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3910-6	2.2	463
87	Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 517-22	15.1	385
86	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 309-25	220.7	287
85	Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. <i>Annals of Oncology</i> , 2002 , 13, 710-5	10.3	222
84	The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. <i>Journal of the American College of Cardiology</i> , 2017 , 49, 170-80	15.1	200
83	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017 , 19, 9-42	12.3	189
82	N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. <i>Clinical Chemistry</i> , 2005 , 51, 1405-10	5.5	172
81	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. <i>Circulation: Heart Failure</i> , 2016 , 9, e002661	7.6	156
80	Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. <i>American Journal of Clinical Pathology</i> , 2008 , 130, 688-95	1.9	137
79	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. <i>European Journal of Heart Failure</i> , 2020 , 22, 1945-1960	12.3	127
78	Role of biomarkers in chemotherapy-induced cardiotoxicity. <i>Progress in Cardiovascular Diseases</i> , 2010 , 53, 121-9	8.5	113

77	Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3157-65	2.2	102
76	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneTrial. <i>European Journal of Cancer</i> , 2018 , 94, 126-137	7.5	98
75	Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. <i>Clinical Chemistry</i> , 2003 , 49, 248-52	5.5	94
74	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. <i>Circulation: Heart Failure</i> , 2016 , 9, e002843	7.6	84
73	Increased perioperative N-terminal pro-B-type natriuretic peptide levels predict atrial fibrillation after thoracic surgery for lung cancer. <i>Circulation</i> , 2007 , 115, 1339-44	16.7	78
72	Strategies to prevent and treat cardiovascular risk in cancer patients. <i>Seminars in Oncology</i> , 2013 , 40, 186-98	5.5	72
71	Postoperative B-type natriuretic peptide for prediction of major cardiac events in patients undergoing noncardiac surgery: systematic review and individual patient meta-analysis. <i>Anesthesiology</i> , 2013 , 119, 270-83	4.3	70
70	Atrial fibrillation after operation for lung cancer: clinical and prognostic significance. <i>Annals of Thoracic Surgery</i> , 1999 , 68, 1827-31	2.7	69
69	Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity. <i>International Journal of Cardiology</i> , 2006 , 111, 120-6	3.2	67
68	Cardiotoxicity of Anthracyclines. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 26	5.4	66
67	The compelling need for a cardiology and oncology partnership and the birth of the International CardioOncology Society. <i>Progress in Cardiovascular Diseases</i> , 2010 , 53, 88-93	8.5	65
66	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1811-1823	12.3	61
65	Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. <i>European Heart Journal</i> , 2020 , 41, 1720-1729	9.5	57
64	Cardiac toxicity of anticancer agents. <i>Current Cardiology Reports</i> , 2013 , 15, 362	4.2	51
63	Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. <i>Chest</i> , 2004 , 126, 1412-6	5.3	51
62	Doxorubicin and trastuzumab regimen induces biventricular failure in mice. <i>Journal of the American Society of Echocardiography</i> , 2014 , 27, 568-79	5.8	49
61	Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 245-256	3.8	44
60	Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss. <i>Current Cardiology Reports</i> , 2016 , 18, 51	4.2	42

59	Cardiac toxicity in cancer survivors. <i>Cancer</i> , 2013 , 119 Suppl 11, 2131-42	6.4	36
58	Prevention of Atrial Fibrillation in High-risk Patients Undergoing Lung Cancer Surgery: The PRESAGE Trial. <i>Annals of Surgery</i> , 2016 , 264, 244-51	7.8	33
57	Role of biomarkers in cardioncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011 , 49, 1937-48	5.9	32
56	Managing cardiotoxicity of chemotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013 , 15, 410-24	2.1	28
55	Intrapericardial treatment of neoplastic pericardial effusions. <i>Herz</i> , 2000 , 25, 787-93	2.6	28
54	Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008 , 10, 486-95	2.1	27
53	Acute coronary syndrome induced by oral capecitabine. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 251-3	3.8	27
52	Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. <i>American Journal of Cardiology</i> , 1991 , 68, 492-7	3	26
51	Cardiac complications of chemotherapy: role of biomarkers. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014 , 16, 313	2.1	24
50	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 2290-2309	12.3	22
49	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.. <i>European Heart Journal</i> , 2021 ,	9.5	21
48	Using cardiac biomarkers and treating cardiotoxicity in cancer. <i>Future Cardiology</i> , 2013 , 9, 105-18	1.3	20
47	Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts. <i>Current Oncology Reports</i> , 2017 , 19, 55	6.3	16
46	Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 480-504	220.7	16
45	Acute kidney injury after lung cancer surgery: Incidence and clinical relevance, predictors, and role of N-terminal pro B-type natriuretic peptide. <i>Lung Cancer</i> , 2018 , 123, 155-159	5.9	15
44	Assessment of cardiotoxicity with cardiac biomarkers in cancer patients. <i>Herz</i> , 2011 , 36, 325-32	2.6	13
43	Circulating cytochrome c as potential biomarker of impaired reperfusion in ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2010 , 106, 1443-9	3	12
42	Troponin I and cardiovascular risk stratification in patients with testicular cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3508; author reply 3508-9	2.2	12

41	Circulating MicroRNAs as Potential Predictors of Anthracycline-Induced Troponin Elevation in Breast Cancer Patients: Diverging Effects of Doxorubicin and Epirubicin. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	11
40	Diagnostic and Prognostic Utility of Circulating Cytochrome c in Acute Myocardial Infarction. <i>Circulation Research</i> , 2016 , 119, 1339-1346	15.7	11
39	TnI-Ultra assay measurements in cancer patients: comparison with the conventional assay and clinical implication. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014 , 74, 385-91	2	11
38	Atrial fibrillation after thoracic surgery for lung cancer: use of a single cut-off value of N-terminal pro-B type natriuretic peptide to identify patients at risk. <i>Biomarkers</i> , 2010 , 15, 259-65	2.6	11
37	Cardiac dysfunction after cancer treatment. <i>Texas Heart Institute Journal</i> , 2011 , 38, 248-52	0.8	11
36	Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). <i>Ecancermedicalscience</i> , 2014 , 8, 433	2.7	11
35	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery: A Systematic Review and Meta-Analysis. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e007437	6.4	10
34	Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets. <i>Heart Failure Reviews</i> , 2021 , 26, 881-890	5	10
33	Chemotherapy-induced cardiotoxicity: importance of early detection. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1297-1299	2.5	10
32	Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. <i>ESC Heart Failure</i> , 2020 , 7, 1452-1466	3.7	8
31	Detection and monitoring of cardiotoxicity by using biomarkers: Pros and cons: Remarks on the international colloquium on cardioncology.. <i>Progress in Pediatric Cardiology</i> , 2015 , 39, 77-84	0.4	8
30	Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 611-621	3.9	7
29	The breast cancer patient in the cardioncology unit. <i>Journal of Thoracic Disease</i> , 2018 , 10, S4306-S4322	2.6	6
28	Prokineticin Receptor-1 Signaling Inhibits Dose- and Time-Dependent Anthracycline-Induced Cardiovascular Toxicity Via Myocardial and Vascular Protection. <i>JACC: CardioOncology</i> , 2019 , 1, 84-102	3.8	5
27	Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 59, 51-57	5.9	5
26	Role of Cardiac Biomarkers in Cancer Patients. <i>Cancers</i> , 2021 , 13,	6.6	5
25	High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 513-521	5.9	4
24	Managing cardiac risk factors in oncology clinical trials. <i>Texas Heart Institute Journal</i> , 2011 , 38, 266-7	0.8	4

23	Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
22	Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. <i>Oncologist</i> , 2019 , 24, e1034-e1043	5.7	4
21	How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice. <i>Kardiologia Polska</i> , 2021 , 79, 114-122	0.9	4
20	Oncologic therapies associated with cardiac toxicities: how to minimize the risks. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 359-374	3.5	3
19	Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy". <i>Circulation</i> , 2016 , 133, e363	16.7	3
18	Nonrandomized comparison between concomitant and sequential chemoradiotherapy with anthracyclines in breast cancer. <i>Tumori</i> , 2015 , 101, 64-71	1.7	3
17	Treating asymptomatic chemotherapy-induced cardiac dysfunction: a chance that cardiologists and oncologists should not miss. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1790; author reply 1790-1	15.1	2
16	Incidence, Management, Prevention and Outcome of Post-Operative Atrial Fibrillation in Thoracic Surgical Oncology. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	2
15	Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1190	5.6	2
14	Acute kidney injury: a common prognostic condition for different pathogenetic triggers?. <i>Journal of Thoracic Disease</i> , 2019 , 11, E112-E114	2.6	1
13	Treatment and prevention of cardiotoxicity due to anticancer therapy. <i>Journal of Cardiovascular Echography</i> , 2011 , 21, 92-100	0.6	1
12	Association of Breast Cancer Irradiation With Cardiac Toxic Effects: A Narrative Review. <i>JAMA Oncology</i> , 2021 , 7, 924-932	13.4	1
11	Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021 , 23, 1	2.1	1
10	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation.. <i>Journal of Cardiovascular Translational Research</i> , 2022 , 1	3.3	1
9	Cancer Cardiotoxicity and Cardiac Biomarkers. <i>Biomarkers in Disease</i> , 2015 , 73-105		0
8	Subclinical cardiac damage in cancer patients before chemotherapy. <i>Heart Failure Reviews</i> , 2021 , 1	5	0
7	Cancer Cardiotoxicity and Cardiac Biomarkers 2014 , 1-26		
6	Reply to R. Steiner et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1380	2.2	

- 5 Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo. *Journal of Cardiovascular Echography*, **2011**, 21, 32-41 0.6
- 4 Reply to S. Goel et al and P.A. Kavsak et al. *Journal of Clinical Oncology*, **2011**, 29, e178-e179 2.2
- 3 Cardiotoxicity: Left Ventricular Dysfunction **2017**, 123-141
- 2 Diagnostic Tests in Cardio-oncology **2016**, 313-343
- 1 Heart Failure in Oncologic Patients **2016**, 511-533